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Platelet count and mean volume (MPV) in association with plasma HCO3
-
in regular hemodialysis patients
Parâmetros hematológicos associados ao HC0
3
- plasmático de pacientes em hemodiálise
Hamid Nasri1
Azar Baradaran2
End-stage renal failure often is associated with abnormal bleeding that may represent
an important complication of this disorder. The hemorrhagic tendency currently is
attributed to altered primary hemostasis, mainly platelet dysfunction. The aim of the
present study was to elucidate whether and how in patients, with uremia on
hemodialysis, the level of plasma HCO3
- affects the mean PLT volume (MPV) and
count. The total patients were 36 (f=15, m=21). The mean patients' age was 46 (±16)
years. The mean length of the time patients had received hemodialysis was 32 (±36)
months. The mean PLT count was 165 (±70) [x10³µ/L]. The mean MPV was 9 (±1) fl.
The mean plasma HCO3
- was 20 (±2.6) mEq/L. In this study a significant inverse
correlation of PLT count with MPV and a significant positive association of PLT
count with plasma HCO3 and also a significant inverse correlation of MPV with
plasma HCO3
- were found. Positive association of mild relative acidemia with PLT
count and its negative correlation with MPV may further support the reverse
epidemiology of serum bicarbonate in end-stage renal disease patients on hemodialysis
which needs more attention as a protective role in mild relative acidosis of regular
hemodialysis patients. Rev. bras. hematol. hemoter. 2006;28(2):127-130.
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Introduction
The renal elimination of nonvolatile acids, mainly
formed by oxidation of sulfuric amino acids, is about 70
mmol/day. In hemodialysis (HD) patients cannot eliminate
the excess of H+ via the kidneys.1 Metabolic acidosis is
associated with chronic renal failure (CRF). Often,
maintenance dialysis therapies are not able to reverse this
condition. The major systemic consequences of chronic
metabolic acidosis are increased protein catabolism,
decreased protein synthesis, and a negative protein balance
that improves after bicarbonate supplementation.2 Patients
with end-stage renal disease suffer from complex hemostatic
disorders. Uremic patients show a bleeding diathesis that is
mainly due to abnormalities of primary hemostasis.3,4 The
increased bleeding tendency of chronic renal failure patients
has been attributed to platelet dysfunction.3-5 The most
common abnormalities are defective platelet aggregation,
decreased platelet adhesiveness, decreased availability of
platelet factor-3, and prolongation of the bleeding time.6
Some of the pathophysiologic mechanisms which have been
implicated include platelet inhibition by plasma metabolites,
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e.g., urea, guanidinosuccinic acid, phenolic acid; increased
vessel wall prostacyclin; abnormal platelet arachidonic acid
metabolism and increased levels of parathyroid hormone.6
Recently, an index related to platelet count has been provided
by hematologic analyzers. Concerning the platelet
parameter, the mean platelet volume (MPV) has been
described.7 Platelet volume is a marker and possibly a
determinant of platelet function in that large platelets are
more active than normal sized platelets. Mean platelet vo-
lume (MPV), a measure of platelet size, reflects changes in
either the level of platelet stimulation or the rate of platelet
production.8 Increased mean platelet volume may reflect
increased platelet activation or increased numbers of large,
hyperaggregable platelets, and is accepted as an independent
coronary risk factor.9 Mean platelet volume could also be
an independent risk factor for myocardial infarction in the
general population and also CHD in hemodialysis (HD)
patients.10,11 Regarding the present data, studies concerning
the association of relative acidosis of maintenance
hemodialysis and plasma HCO3
- level with MPV and platelet
count in HD patients are quiet scarce. Therefore, the aim of
the present study was to elucidate whether and how, in
patients with uremia on hemodialysis, the level of plasma
HCO3
- affects the mean PLT volume and count.
Patients and Methods
Patients
This cross-sectional study was conducted on patients
with end-stage renal disease (ESRD), who were undergoing
maintenance hemodialysis treatment with acetate based
dialysate and polysulfone membranes. The study was carried
out in the hemodialysis section of Hajar Medical educational
& Therapeutic Center of Shahrekord University of Medical
Sciences in Shahrekord, Iran. According to the severity of
secondary hyperparathyroidism, each patient being treated
for secondary hyperparathyroidism was given oral active
vitamin D3 (Calcitriol; Rocaltrol) (Roche Hexagon; Roche
Laboratories Inc, New Jersey, USA), calcium carbonate
capsules, and Rena-Gel (sevelamer; Genzyme Europe B.V.;
United Kingdom/Ireland) tablets at various doses. According
to the severity of anemia, patients were prescribed
intravenous iron therapy with iron Sucrose (Venofer -
International Inc. St. Gallen Switzerland) at various doses
after each dialysis session. All patients received treatments
of 6 mg folic acid daily, 500 mg Acetyl- L-Carnitine (Jarrow
Formulas, Inc™ Los Angeles, CA) daily, oral vitamin B-
complex tablets daily, and 2,000 U intravenous Eprex
(recombinant human erythropoietin [Rhuepo] [Janssen-
Cilag; Cilag - AG International 6300 Zug, Switzerland) after
each dialysis session. Exclusion criteria were active or
chronic infection and use of NSAID or ACE inhibitor drugs
and also the use of other drugs that have adverse effects on
platelet production or function.
 Laboratory methods
Blood samples were collected after overnight fasting
from patients, complete blood count containing WBC count,
hemoglobin (Hgb), hematocrit (Hct), platelet (PLT) count
and also Mean Platelet Volume (MPV) (Ref. Range 7.5 -
11.5 fl) were measured using a Sysmex-KX-21N cell counter
(Sysmex Corporation; Mundelein, Illinois, Sysmex America,
Inc.). Levels of serum iron, ferritin, C-reactive protein
(CRP), calcium (Ca), and also serum albumin (Alb) were
measured using standard kits. serum ferritin was measured
by radioimmunoassay (RIA). Plasma HCO3
- was measured
by arterial blood gas. Duration and dosages of hemodialysis
treatment were calculated from the patients' records. The
duration of each hemodialysis session was 4 hours. For the
efficacy of hemodialysis the urea reduction rate (URR) was
calculated from pre- and post-blood urea nitrogen (BUN)
data.
Statistical analysis
Results are expressed as means ± SD. Statistical
correlations were assessed using the partial correlation test.
All statistical analyses were performed using SPSS (SPSS
Inc, Chicago, IL; version 11.5.00). Statistical significance
was determined at a p-value lower than 0.05.
Results
The total patients were 36 (f=15, m=21). Table 1
summarized patients' data. The mean patients' age was 46
(±16) years. The mean length of time patients had received
hemodialysis was 32 (±36) months. The mean PLT count
was 165 (±70) [x10³µ/l]. The mean MPV was 9 (±1) fl.
The mean plasma HCO3
- was 20 (±2.6) mEq/l. In this study
a significant inverse correlation of PLT count with MPV
(r= -0.54, p = 0.001) (adjusted for age) was seen. A
significant positive association of PLT count with plasma
HCO3- (r= -0.40, p = 0.048) (adjusted for age, duration and
doses of dialysis, WBC count, Hgb, serum Ca, CRP, Alb,
iron and ferritin) and a significant inverse correlation of
MPV with plasma HCO3
- (r= -0.37, p = 0.050; Figure 1)
(adjusted for age, duration and doses of dialysis, WBC count,
serum Ca, Alb, iron and ferritin) were seen too.
Discussion
 In this study we found a significant inverse correlation
of PLT count with MPV. A significant positive association
of PLT count with plasma HCO3 and a significant inverse
correlation of MPV with plasma HCO3
- were also found.
The greatest role in the development of haemostatic
disturbances in patients with chronic renal failure (CRF) is
ascribed to the platelets. Although the platelet parameter,
the mean platelet volume has been routinely available to
clinicians for some time, its role in the diagnosis and
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management of patients remains unclear. While factors affect
PLT count and volume during hemodialysis is under
investigation, it is believed that platelet activation and
aggregation, and coagulative activation are the earliest and
most important phenomena that occur after contact between
blood and artificial membranes.12 Mean platelet volume is a
physiological variable of hemostatic importance.13 Large
platelets are more reactive, produce more prothrombotic
factors13-15 and aggregate more easily. They also contain more
dense granules and release more serotonin and ß-
thromboglobulin than small platelets do.15-17 Platelets have
no nuclei and their characteristics are determined by their
progenitor cell, the bone marrow megakaryocyte. It is
generally accepted that platelet volume and density are
determined at thrombopoiesis and that, once in the
circulation, platelets do not change in size.17-19 The
mechanisms controlling platelet production are obscure,
although it has been suggested that both MPV and platelet
counts are under independent hormonal control,19-22 however
larger platelets are more reactive.22,23 The inverse association
of PLT counts and MPV which was shown in our study was
also shown in the studies conducted by Bancroft and
Lamparelli et al.22-24 Lamparelli showed an inverse
correlation between platelet volume and platelet number in
564 normal subjects and 297 pregnant women.24 Available
data suggest that metabolic acidosis is both catabolic and
anti-anabolic.2 In contrast to the metabolic studies, many
epidemiologic studies in maintenance dialysis patients have
indicated a paradoxically inverse association between mildly
decreased serum bicarbonate and improved markers of
protein-energy nutritional state. Hence metabolic acidosis
may be considered as yet another element of the reverse
epidemiology in ESRD patients. Interventional studies have
yielded inconsistent results in CKD and ESRD patients,
although in peritoneal dialysis patients, mitigating acidemia
appears to more consistently improve nutritional status and
reduce hospitalizations.25 In this study, the positive
association of mild relative academia with PLT count and
its negative correlation with MPV may further support the
reverse epidemiology of serum bicarbonate in ESRD patients
on hemodialysis. To our knowledge this is the first study,
concerning the association on plasma HCO3- with PLT count
and MPV. Our conclusion is that more attention is required
for hemodialysis patients.
Resumo
O estágio terminal de suficiência renal freqüentemente está  asso-
ciado a sangramentos anormais e que representam complicações
importantes na evolução desta moléstia. A tendência hemorrágica
é atribuída a alterações primárias de hemostasia, decorrentes prin-
cipalmente  da disfunção plaquetária. O objetivo deste estudo foi
o de elucidar quando como pacientes urêmicos, em hemodiálise
o nível de HCO3 afeta a contagem plaquetária e o seu volume
médio. O número de pacientes estudados foi 36 (fem.15, masc. =
21). A idade foi de 46 ± 16 anos.  A contagem média das plaquetas
foi de 165(± 70) x 103µ/l, o volume médio foi de 9 (± 1) fl. O HCO3
plasmático médio foi de 20 (± 2,6) mEq/l. No estudo foi observa-
da uma correlação inversa entre a contagem plaquetária e o
volume médio associado com associação positiva  significante
das plaquetas com o HCO3 do plasma e também correlação sig-
Table 1
Mean ±SD, minimum and maximum of age, duration and doses of
hemodialysis and also laboratory results of patients
Total patients = 36 Minimum Maximum Mean
Age years 16 80 46±16
DH* months 2 156 32±36
Dialysis
dose sessions 36 1584 294±393
URR% 39 76 59±9
Creat mg/dl 3 18 9±3
BUN mg/dl 30 180 82±33
Ca mg/dl 5 10 7.6±0.9
Iron micg/dl 10 1515 350±454
Alb g/dl 2.4 4.8 3.8±0.5
PLT count
[x10³u/l] 264 396 165±70
MPV fl 7 11 9±1
Ferritin ng/dl 35 1250 518±299
CRP mg/l 3 40 8.7±6.6
Hgb g/dl 5 13 9±2
HCT% 14 40 28±6
WBC count
cells/mm3 1000 11200 5600±2000
HCO3- mEq/l 14 25 20±2.5
*Duration of hemodialysis treatment
Figure 1. Significant inverse correlation of MPV with plasma HCO3-
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nificativa inversa do volume médio plaquetário e HCO3 plasma.
A associação positiva e sua correlação negativa com o volume
médio plaquetário podem sugerir reversão da epidemiologia do
estágio terminal de insuficiência renal de pacientes em hemo-
diálise que necessitam de maior proteção quando da acidose
leve em vigência de hemodiálise. Rev. bras. hematol. hemoter.
2006;28(2):127-130.
Palavras-chave: Plaquetas; hemodiálise; insuficiência renal;
volume médio plaquetário; HCO3
- plasmático.
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